Brief: Synact Pharma Announces Additional Data From Expand P2b Clinical Trial
03/10/2023 06:07
Oct 3 (Reuters) - SynAct Pharma AB SYNACT.ST :
* SYNACT PHARMA ANNOUNCES ADDITIONAL DATA FROM THE EXPAND
P2B
CLINICAL TRIAL FURTHER SUPPORTING EFFICACY AND ACTIVITY SEEN IN
PATIENTS WITH ELEVATED CRP
Source text for Eikon: ID:nMFN7gDrqS
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development